Short Wave Podcast Summary

Episode: These bacteria may be key to the fight against antibiotic resistance

Date: February 9, 2026
Host: Regina Barber (NPR)
Guest: Natalie Balaban, Biophysicist, Hebrew University, Jerusalem

Overview

This episode dives into the science of antibiotic persistence—a phenomenon distinct from resistance—which could hold the key to countering the growing threat of antibiotic-resistant bacteria. Host Regina Barber and guest Natalie Balaban unpack recent discoveries showing how dormant (persistor) bacteria survive antibiotics and later fuel the evolution of resistance. They discuss a new study from Balaban’s lab, revealing mechanisms behind this dormancy and offering hope for new, more effective drug strategies.

Key Discussion Points & Insights

1. Origins of Antibiotic Resistance

• Brief History:
  Regina recounts Alexander Fleming’s discovery of penicillin in 1928 and the lifesaving power of antibiotics, followed by the increasing threat of antibiotic resistance.

  “Since then, penicillin and other antibiotics have saved millions of lives with one problem, the growing threat of antibiotic resistance.” (00:22)

2. Defining Resistance vs. Persistence

• Antibiotic Resistance
  Natalie Balaban explains resistance as genetic mutations that let bacteria survive antibiotics:

  “Antibiotic resistance means that somehow the bacterium usually acquired a mutation... it doesn’t do its job and… the bacterium grows happily and it's resistant to penicillin.” (00:56)

• Antibiotic Persistence
  Balaban’s main focus is on persistence:

  • Some bacteria evade antibiotics by entering a dormant, non-growing state.
  • Antibiotics like penicillin target growing, metabolically active bacteria—so dormant ones survive.

  “The penicillin will kill all the growing ones, but the ones that are not growing are going to persist.” (01:54)

3. Clinical Overlook of Persistence

• Most clinicians focus on resistance, but persistence can undermine treatments—especially in immunocompromised patients.

  “In a healthy patient, it's enough for the antibiotic to kill most of the bacteria or even just to arrest the growth. But... in immunocompromised [patients], persistence leads to resistance, and these resistant strains can go and infect other people.” (04:59)

4. Persistence as a Stepping Stone to Resistance

• Balaban’s research confirms that persistence often precedes and enables the evolution of resistance.

  “Persistence. Antibiotic persistence is really a stepping stone for antibiotic resistance... if you are not taking care also of the persistent bacteria, then they will eventually evolve to be resistant to this drug.” (05:59)

5. New Insights into Dormancy: The 'Car Crash' Model

• Historically, dormancy was viewed as an orderly shutdown. Balaban’s new study finds that it can occur through “chaotic” or accidental events—likened to a car crash:

  “You haven't parked your car... you had a car crash and now your car is not moving. This car crash didn't kill them, but it made them stop their growth. And... instead of being bad, turned out to be beneficial because now... they survive the antibiotic treatment." (06:50, 07:41)

  • In infections, contact with immune cells (even if the cell fails to kill the bacterium) can trigger such chaotic dormancy.
  • These bacteria stay dormant, sometimes for days, and may reignite infection once antibiotics are stopped.

  “Their recovery is going to be very, very long... this chaotic bacteria will [eventually] start growing again, and then you'll have a reinfection.” (08:41)

6. Implications for Treatment Strategies

• Dormant bacteria in this disordered state have more permeable membranes. This vulnerability could be a target for new drugs.

  “Their membrane is more permeable... now there are all kind of ideas of how to take advantage of this increased membrane permeability to actually use all kind of compounds that can kill them.” (09:58, 10:15)

• The pathway forward may involve two-step therapies:

  1. Standard antibiotics to kill active bacteria
  2. Membrane-targeting drugs for dormant, chaotic bacteria before ending treatment.

  “Let’s use a compound that is specific against these chaotic bacteria and then stop the treatment.” (11:28)

Notable Quotes & Memorable Moments

• On persistence feeding resistance:

  “Persistence leads to resistance, and these resistant strains actually can go and infect other people.” —Natalie Balaban (04:59)

• ‘Car crash’ analogy for dormancy:

  “This car crash didn’t kill them, but it made them stop their growth.” —Natalie Balaban (07:41)

• Clinical implications:

  “The chaos that is governing the recovery time of these bacteria is also actually dictating how long the treatment should be.” —Natalie Balaban (09:47)

Important Timestamps for Key Segments

• 00:22 — Penicillin discovery and intro to resistance
• 00:56 — Defining antibiotic resistance
• 01:54 — Defining antibiotic persistence
• 03:28 — Difference between resistance and persistence
• 04:17 — Dormancy’s role in survival
• 05:59 — Link between persistence and resistance
• 06:50 — The ‘car crash’ dormancy model
• 08:41 — Relevance of dormancy’s chaos for reinfection
• 09:58 — Targeting chaotic persisters
• 11:28 — Two-step strategy for future drug development

Tone & Style

The conversation is approachable yet precise, blending curiosity with scientific rigor. Balaban uses analogies (“car crash” dormancy) that make complex mechanisms relatable, while Regina prompts with clarifying questions and keeps a tone of accessibility and engagement.

Summary

This compact episode puts a spotlight on a paradigm shift in fighting antibiotic resistance—namely, by understanding and targeting bacterial persistence in addition to resistance. Natalie Balaban’s research shows that dormant, chaotic bacteria could be the linchpin in both treating persistent infections and slowing the march of resistance. New therapies that exploit their temporary vulnerabilities may redefine the future of antibiotics.